英文名稱 | Linifanib(ABT-869; AL-39324; RG3635) |
---|---|
中文名稱 | 利尼伐尼 |
CAS號 | 796967-16-3 |
分子式 | C21H18FN5O |
分子量 | 375.40 |
外觀 | White to gray powder |
英文名稱 | Linifanib(ABT-869; AL-39324; RG3635) |
---|---|
中文名稱 | 利尼伐尼 |
CAS號 | 796967-16-3 |
分子式 | C21H18FN5O |
分子量 | 375.40 |
外觀 | White to gray powder |
Linifanib (formerly RG3635, ABT869, AL39324) is an orally bioavailable and ATP-competitive inhibitor of multiple kinases (e.g. VEGFR/PDGFR) with potential antitumor activity. Its IC50 values are 4 nM, 3 nM, 3 nM/4 nM, and 66 nM for KDR, CSF-1R, Flt-1/3, and PDGFRβ, respectively. Linifanib has strong antitumor efficaciousness in vivo and outstanding anti-proliferative activity in vitro.